Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Gelita AG has a patent portfolio in the Chemistry & Materials technology area. There are currently 2 pending office actions. These actions are being handled by 2 distinct examiners across 2 distinct art units, showing a lack of concentration in the review of these chemistry filings.
MELLOTT, JAMES M is the busiest examiner, with 1 busiest examiner pending action. With 2 pending office actions total, the workload is divided equally between the two examiners. The involvement of 2 distinct art units indicates that the company's chemistry and materials filings are being reviewed by different specialized technical groups. This requires the company to manage two separate prosecution tracks, each subject to the different standards and expectations of two distinct examiners and two different art units.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MELLOTT, JAMES M | 1 | 51.1% | +44.1% |
| KOMATSU, LI N | 1 | 59.8% | +71.0% |
| AFREMOVA, VERA | 1 | 50.5% | +29.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17736430 | METHOD FOR PRODUCING COLLAGEN PEPTIDES FROM BONES, AND PRODUCED COLLAGEN PEPTIDES | AFREMOVA, VERA | 4d overdue |
| 18911469 | METHOD FOR INCREASING THE EFFICIENCY OF A SOLAR MODULE OR A SOLAR COLLECTOR | MELLOTT, JAMES M | 1d overdue |
| 18131524 | COLLAGEN HYDROLYSATE AS AN ACTIVE SUBSTANCE FOR DELAYING AGEING | KOMATSU, LI N | 1d overdue |
| Art Unit | Apps |
|---|---|
| 1759 | 1 |
| 1658 | 1 |
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18911469 | METHOD FOR INCREASING THE EFFICIENCY OF A SOLAR MODULE OR A SOLAR COLLECTOR | MELLOTT, JAMES M | 1759 | §103 | Final Rejection | 1d overdue | Pending | Oct 10, 2024 |
| 18131524 | COLLAGEN HYDROLYSATE AS AN ACTIVE SUBSTANCE FOR DELAYING AGEING | KOMATSU, LI N | 1658 | §103 | Final Rejection | 1d overdue | Pending | Apr 06, 2023 |
| 17736430 | METHOD FOR PRODUCING COLLAGEN PEPTIDES FROM BONES, AND PRODUCED COLLAGEN PEPTIDES | AFREMOVA, VERA | 1653 | §103 | Final Rejection | 4d overdue | Pending | May 04, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGelita AG has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
James M Mellott has the most, with 1 of Gelita AG's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
